Form 8-K - Current report:
SEC Accession No. 0001193125-25-331147
Filing Date
2025-12-23
Accepted
2025-12-23 17:18:31
Documents
11
Period of Report
2025-12-17
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20251217.htm   iXBRL 8-K 62041
2 EX-10.1 tcrt-ex10_1.htm EX-10.1 45844
  Complete submission text file 0001193125-25-331147.txt   218944

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20251217.xsd EX-101.SCH 28388
13 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20251217_htm.xml XML 4720
Mailing Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301
Business Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 251601737
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)